UA100227C2 - Заміщені n-фенілметил-5-оксопролін-2-аміди як антагоністи p2x7-рецептора та їх застосування - Google Patents
Заміщені n-фенілметил-5-оксопролін-2-аміди як антагоністи p2x7-рецептора та їх застосуванняInfo
- Publication number
- UA100227C2 UA100227C2 UAA200900103A UAA200900103A UA100227C2 UA 100227 C2 UA100227 C2 UA 100227C2 UA A200900103 A UAA200900103 A UA A200900103A UA A200900103 A UAA200900103 A UA A200900103A UA 100227 C2 UA100227 C2 UA 100227C2
- Authority
- UA
- Ukraine
- Prior art keywords
- oxo
- phenylmethyl
- proline
- amides
- substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
- C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D207/28—2-Pyrrolidone-5- carboxylic acids; Functional derivatives thereof, e.g. esters, nitriles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
- C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Даний винахід стосується нових оксопролінамідних похідних формули (І), що модулюють функцію Р2Х7-рецептора і здатні викликати антагонізм у відношенні впливів АТФ на Р2Х7-рецептор, і застосування таких сполук або фармацевтичних композицій, що їх містять, при лікуванні порушень, опосередковуваних Р2Х7-рецептором, наприклад, болю, запалення й нейродегенерації. EMBED ISISServer . (I)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0613473A GB0613473D0 (en) | 2006-07-06 | 2006-07-06 | Novel compounds |
GB0622825A GB0622825D0 (en) | 2006-11-15 | 2006-11-15 | Novel compounds |
GB0705263A GB0705263D0 (en) | 2007-03-19 | 2007-03-19 | Novel compounds |
GB0711439A GB0711439D0 (en) | 2007-06-13 | 2007-06-13 | Novel receptor antagonists and their methods of use |
PCT/EP2007/056675 WO2008003697A1 (en) | 2006-07-06 | 2007-07-03 | Substituted n-phenylmethyl -5-oxo-proline-2-amides as p2x7-receptor antagonists and their methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
UA100227C2 true UA100227C2 (uk) | 2012-12-10 |
Family
ID=38508907
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UAA200900103A UA100227C2 (uk) | 2006-07-06 | 2007-07-03 | Заміщені n-фенілметил-5-оксопролін-2-аміди як антагоністи p2x7-рецептора та їх застосування |
Country Status (26)
Country | Link |
---|---|
US (2) | US7718693B2 (uk) |
EP (1) | EP2049478B1 (uk) |
JP (1) | JP5283620B2 (uk) |
KR (2) | KR20140016431A (uk) |
AR (1) | AR061815A1 (uk) |
AU (1) | AU2007271182B2 (uk) |
BR (1) | BRPI0714062A2 (uk) |
CA (1) | CA2655675A1 (uk) |
CR (2) | CR10545A (uk) |
CY (1) | CY1113415T1 (uk) |
DK (1) | DK2049478T3 (uk) |
EA (1) | EA016076B1 (uk) |
ES (1) | ES2385505T3 (uk) |
HK (1) | HK1127604A1 (uk) |
HR (1) | HRP20120505T1 (uk) |
IL (1) | IL196181A0 (uk) |
MA (1) | MA30607B1 (uk) |
MX (1) | MX2009000117A (uk) |
NO (1) | NO20090267L (uk) |
PE (1) | PE20080997A1 (uk) |
PL (1) | PL2049478T3 (uk) |
PT (1) | PT2049478E (uk) |
SI (1) | SI2049478T1 (uk) |
TW (1) | TW200819127A (uk) |
UA (1) | UA100227C2 (uk) |
WO (1) | WO2008003697A1 (uk) |
Families Citing this family (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL2049500T3 (pl) | 2006-07-06 | 2012-02-29 | Array Biopharma Inc | Cyklopenta[d]pirymidyny jako inhibitory kinaz białkowych AKT |
ATE532789T1 (de) | 2006-07-06 | 2011-11-15 | Array Biopharma Inc | Dihydrothienopyrimidine als akt-proteinkinase- inhibitoren |
DE602007011628D1 (de) | 2006-07-06 | 2011-02-10 | Array Biopharma Inc | Dihydrofuropyrimidine als akt-proteinkinaseinhibitoren |
US8063050B2 (en) | 2006-07-06 | 2011-11-22 | Array Biopharma Inc. | Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
UA100227C2 (uk) | 2006-07-06 | 2012-12-10 | Глаксо Груп Лімітед | Заміщені n-фенілметил-5-оксопролін-2-аміди як антагоністи p2x7-рецептора та їх застосування |
DE102006047619B4 (de) * | 2006-10-09 | 2008-11-13 | Clariant International Limited | Verfahren zur Herstellung basischer Fettsäureamide |
DE102006047617B4 (de) * | 2006-10-09 | 2008-11-27 | Clariant International Limited | Verfahren zur Herstellung basischer (Meth)acrylamide |
EP3034046B1 (en) * | 2006-10-22 | 2018-01-17 | IDEV Technologies, INC. | Methods for securing strand ends and the resulting devices |
GB0705882D0 (en) | 2007-03-27 | 2007-05-02 | Glaxo Group Ltd | Novel compounds |
WO2008116845A1 (en) * | 2007-03-28 | 2008-10-02 | Glaxo Group Limited | Piperidinone carboxamide derivatives as p2x7 modulators |
EP2139875A2 (en) * | 2007-03-29 | 2010-01-06 | Glaxo Group Limited | Oxazolidine and morpholine carboxamide derivatives as p2x7 modulators |
EP2142512A2 (en) | 2007-04-03 | 2010-01-13 | Glaxo Group Limited | Imidazolidine carboxamide derivatives as p2x7 modulators |
CN103396409B (zh) | 2007-07-05 | 2015-03-11 | 阵列生物制药公司 | 作为akt蛋白激酶抑制剂的嘧啶基环戊烷 |
US9409886B2 (en) | 2007-07-05 | 2016-08-09 | Array Biopharma Inc. | Pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
US8846683B2 (en) | 2007-07-05 | 2014-09-30 | Array Biopharma, Inc. | Pyrimidyl cyclopentanes as Akt protein kinase inhibitors |
US8377937B2 (en) | 2007-07-05 | 2013-02-19 | Array Biopharma Inc. | Pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
WO2009074518A1 (en) * | 2007-12-12 | 2009-06-18 | Glaxo Group Limited | Combinations of prolinamide p2x7 modulators with further therapeutic agents |
AU2008337506A1 (en) * | 2007-12-18 | 2009-06-25 | Glaxo Group Limited | 5-oxo-3-pyrrolidinecarboxamide derivatives as P2X7 modulators |
GB0724625D0 (en) * | 2007-12-18 | 2008-01-30 | Glaxo Group Ltd | Novel compounds |
US8835434B2 (en) | 2008-01-09 | 2014-09-16 | Array Biopharma, Inc. | Hydroxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors |
US8853216B2 (en) | 2008-01-09 | 2014-10-07 | Array Biopharma, Inc. | Hydroxylated pyrimidyl cyclopentane as AKT protein kinase inhibitor |
GB0803729D0 (en) * | 2008-02-29 | 2008-04-09 | Ge Healthcare Ltd | Imaging the central nervous system |
CA2719745C (en) | 2008-03-25 | 2016-07-05 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
DE102008017216B4 (de) * | 2008-04-04 | 2013-08-14 | Clariant International Ltd. | Kontinuierliches Verfahren zur Herstellung von Fettsäureamiden |
DE102008017213B4 (de) * | 2008-04-04 | 2012-08-09 | Clariant International Limited | Kontinuierliches Verfahren zur Herstellung von Amiden aliphatischer Hydroxycarbonsäuren |
DE102008017217A1 (de) * | 2008-04-04 | 2009-10-08 | Clariant International Ltd. | Kontinuierliches Verfahren zur Herstellung von Amiden aromatischer Carbonsäuren |
DE102008017219A1 (de) * | 2008-04-04 | 2009-10-08 | Clariant International Ltd. | Verfahren zur Herstellung von Amiden in Gegenwart von überhitztem Wasser |
DE102008017214B4 (de) * | 2008-04-04 | 2012-02-16 | Clariant International Limited | Kontinuierliches Verfahren zur Herstellung von Fettsäurealkanolamiden |
DE102008017218B4 (de) * | 2008-04-04 | 2011-09-22 | Clariant International Ltd. | Kontinuierliches Verfahren zur Herstellung von Amiden niederer aliphatischer Carbonsäuren |
DE102008017215B4 (de) * | 2008-04-04 | 2012-08-09 | Clariant International Ltd. | Kontinuierliches Verfahren zur Herstellung von Amiden ethylenisch ungesättigter Carbonsäuren |
JP5583694B2 (ja) * | 2009-01-05 | 2014-09-03 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Cb2受容体を調節するピロリジン化合物 |
AU2010237302A1 (en) | 2009-04-14 | 2011-12-01 | Affectis Pharmaceuticals Ag | Novel P2X7R antagonists and their use |
DE102009031059A1 (de) | 2009-06-30 | 2011-01-05 | Clariant International Ltd. | Vorrichtung zur kontinuierlichen Durchführung chemischer Reaktionen bei hohen Temperaturen |
DE102009042523B4 (de) | 2009-09-22 | 2012-02-16 | Clariant International Ltd. | Vorrichtung und Verfahren zur kontinuierlichen Durchführung heterogen katalysierter chemischer Reaktionen bei hohen Temperaturen |
DE102009042522A1 (de) | 2009-09-22 | 2011-04-07 | Clariant International Ltd. | Kontinuierliches Umesterungsverfahren |
DK2848256T3 (en) | 2009-12-08 | 2019-03-04 | Univ Vanderbilt | Improved vein harvesting and autotransplantation methods and compositions |
CA2792258A1 (en) | 2010-03-05 | 2011-09-09 | President And Fellows Of Harvard College | Induced dendritic cell compositions and uses thereof |
JP2013526496A (ja) | 2010-05-14 | 2013-06-24 | アフェクティス ファーマシューティカルズ アーゲー | P2x7r拮抗剤の新規調製方法 |
DE102010056564A1 (de) | 2010-12-30 | 2012-07-05 | Clariant International Limited | Hydroxylgruppen und Estergruppen tragende Polymere und Verfahren zu ihrer Herstellung |
DE102010056565A1 (de) | 2010-12-30 | 2012-07-05 | Clariant International Ltd. | Verfahren zur Modifizierung Hydroxylgruppen tragender Polymere |
JP5921572B2 (ja) * | 2011-01-04 | 2016-05-24 | ノバルティス アーゲー | 加齢性黄斑変性症(amd)の処置に有用なインドール化合物またはそのアナログ |
WO2012110190A1 (en) | 2011-02-17 | 2012-08-23 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
CA2828456C (en) * | 2011-03-03 | 2021-05-04 | Zalicus Pharmaceuticals Ltd. | N-benzl-amino-carboxamide inhibitors of the sodium channel |
BR112013025353A8 (pt) | 2011-04-01 | 2018-01-02 | Genentech Inc | combinação de a) um composto de fórmula ia, composto de fórmula ia ou um sal farmaceuticamente aceitável do mesmo, método para tratamento de um distúrbio hiperproliferativo em um mamífero, uso de um composto de fórmula ia ou um sal farmaceuticamente aceitável do mesmo, kit e produto |
JP6147246B2 (ja) | 2011-04-01 | 2017-06-14 | ジェネンテック, インコーポレイテッド | Akt及びmek阻害剤化合物の組み合わせ、及び使用方法 |
WO2012163456A1 (en) | 2011-05-27 | 2012-12-06 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
WO2012163792A1 (en) | 2011-05-27 | 2012-12-06 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
AU2012288511A1 (en) | 2011-07-22 | 2014-03-13 | Actelion Pharmaceuticals Ltd | Heterocyclic amide derivatives as P2X7 receptor antagonists |
US9409917B2 (en) | 2012-01-20 | 2016-08-09 | Actelion Pharmaceuticals Ltd. | Heterocyclic amide derivatives as P2X7 receptor antagonists |
US9075975B2 (en) * | 2012-02-21 | 2015-07-07 | Andrew Bud | Online pseudonym verification and identity validation |
MA38192B1 (fr) | 2012-12-12 | 2017-11-30 | Actelion Pharmaceuticals Ltd | Dérivés d'indole carboxamide utilisés en tant qu'antagonistes du récepteur p2x7 |
AR094053A1 (es) | 2012-12-18 | 2015-07-08 | Actelion Pharmaceuticals Ltd | Derivados de indol carboxamida como antagonistas del receptor p2x₇ |
CN104918617B (zh) | 2013-01-22 | 2017-05-10 | 埃科特莱茵药品有限公司 | 作为p2x7受体拮抗剂的杂环酰胺衍生物 |
ES2616883T3 (es) | 2013-01-22 | 2017-06-14 | Actelion Pharmaceuticals Ltd. | Derivados amida heterocíclicos como antagonistas del receptor P2X7 |
TWI636047B (zh) | 2013-08-14 | 2018-09-21 | 英商卡爾維斯塔製藥有限公司 | 雜環衍生物 |
FR3026102A1 (fr) * | 2014-09-19 | 2016-03-25 | Univ Nice Sophia Antipolis | Conjugues d'acide amine-pyridine/pyridinium et leurs utilisations en tant qu'agents biocides |
GB201421083D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | Enzyme inhibitors |
PL3464271T3 (pl) | 2016-05-31 | 2021-01-25 | Kalvista Pharmaceuticals Limited | Pochodne pirazolowe jako inhibitory kalikreiny osoczowej |
GB201609607D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts |
DE102016111711A1 (de) * | 2016-06-27 | 2017-12-28 | Abb Schweiz Ag | Installationsschaltgerät mit einem Gehäuse und mit einer Schraubanschlussklemme |
MY195013A (en) * | 2017-03-13 | 2022-12-31 | Raqualia Pharma Inc | Tetrahydroquinoline derivatives as p2x7 receptor antagonists |
US20200123104A1 (en) * | 2017-06-28 | 2020-04-23 | Indiana University Research And Technology Corporation | Pharmaceutical agent that binds the p2x7 receptor |
GB201719881D0 (en) | 2017-11-29 | 2018-01-10 | Kalvista Pharmaceuticals Ltd | Solid forms of plasma kallikrein inhibitor and salts thereof |
HRP20220367T1 (hr) | 2017-11-29 | 2022-05-27 | Kalvista Pharmaceuticals Limited | Oblici za doziranje koji sadrže plazmatski kalikrein inhibitor |
JP2021520405A (ja) * | 2018-03-29 | 2021-08-19 | サントル ナショナル ドゥ ラ ルシェルシュ シアンティフィック | 療法におけるp2rx7モジュレーター |
EP4010333A1 (en) | 2019-08-09 | 2022-06-15 | Kalvista Pharmaceuticals Limited | Plasma kallikrein inhibitors |
EP4125843A1 (en) | 2020-03-31 | 2023-02-08 | Nomoreitis B.V. | Treatment of hyperinflammatory syndrome |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2651639A (en) * | 1951-08-22 | 1953-09-08 | American Cyanamid Co | 2-pyrrolidone-5-carboxamide derivatives and methods of preparing the same |
FR2273533A1 (fr) * | 1974-06-04 | 1976-01-02 | Ferlux Sa | Nouveaux derives n-substitues d'acides pyrrolidones-2 carboxyliques-5 |
JPH0699307B2 (ja) | 1987-08-20 | 1994-12-07 | キッセイ薬品工業株式会社 | 抗痴呆剤 |
US4772601A (en) | 1988-01-25 | 1988-09-20 | Hoechst-Roussel Pharmaceuticals, Inc. | 5-Substituted 1-(4-(1-pyrrolidinyl)-2-butynyl)-2-pyrrolidinones, pharmaceutical compositions and use |
US6191146B1 (en) | 1995-11-13 | 2001-02-20 | Smithkline Beecham Corporation | Hemoregulatory compounds |
US6054579A (en) * | 1997-06-26 | 2000-04-25 | Leukosite, Inc. | Synthesis of substituted lactams |
SE9704544D0 (sv) * | 1997-12-05 | 1997-12-05 | Astra Pharma Prod | Novel compounds |
SE9704546D0 (sv) * | 1997-12-05 | 1997-12-05 | Astra Pharma Prod | Novel compounds |
CA2355296A1 (en) * | 1998-12-11 | 2000-06-15 | American Biogenetic Sciences, Inc. | Substituted nitrogen heterocyclic compounds and therapeutic uses thereof |
CN1215028C (zh) | 2002-05-24 | 2005-08-17 | 中国科学院上海有机化学研究所 | 外消旋的联二酚的光学拆分方法 |
US7288538B2 (en) * | 2003-02-20 | 2007-10-30 | Encysive Pharmaceuticals, Inc. | Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists |
PT1663185E (pt) * | 2003-09-22 | 2009-02-16 | Onepharm Res & Dev Gmbh | Prevenção e tratamento de perda óssea induzida por inflamação e/ou imunomediada |
WO2007115403A1 (en) * | 2006-04-10 | 2007-10-18 | Painceptor Pharma Corporation | Compositions and methods for modulating gated ion channels |
US20080076924A1 (en) * | 2006-06-30 | 2008-03-27 | Patrick Betschmann | Piperazines as P2X7 antagonists |
UA100227C2 (uk) * | 2006-07-06 | 2012-12-10 | Глаксо Груп Лімітед | Заміщені n-фенілметил-5-оксопролін-2-аміди як антагоністи p2x7-рецептора та їх застосування |
EP2492268A1 (en) * | 2006-07-22 | 2012-08-29 | Oxagen Limited | Compounds having CRTH2 antagonist activity |
EA201300152A1 (ru) * | 2006-11-27 | 2013-07-30 | Х. Лундбекк А/С | Гетероариламидные производные |
DK2124562T3 (en) * | 2007-03-09 | 2016-08-01 | Second Genome Inc | BICYCLOHETEROARYLFORBINDELSER AS P2X7 modulators and uses thereof |
GB0705882D0 (en) * | 2007-03-27 | 2007-05-02 | Glaxo Group Ltd | Novel compounds |
WO2008116845A1 (en) * | 2007-03-28 | 2008-10-02 | Glaxo Group Limited | Piperidinone carboxamide derivatives as p2x7 modulators |
EP2139875A2 (en) * | 2007-03-29 | 2010-01-06 | Glaxo Group Limited | Oxazolidine and morpholine carboxamide derivatives as p2x7 modulators |
EP2142512A2 (en) * | 2007-04-03 | 2010-01-13 | Glaxo Group Limited | Imidazolidine carboxamide derivatives as p2x7 modulators |
WO2008124153A1 (en) * | 2007-04-10 | 2008-10-16 | H. Lundbeck A/S | Heteroaryl amide analogues as p2x7 antagonists |
-
2007
- 2007-07-03 UA UAA200900103A patent/UA100227C2/uk unknown
- 2007-07-03 DK DK07787001.2T patent/DK2049478T3/da active
- 2007-07-03 PL PL07787001T patent/PL2049478T3/pl unknown
- 2007-07-03 KR KR1020147001116A patent/KR20140016431A/ko not_active Application Discontinuation
- 2007-07-03 CA CA002655675A patent/CA2655675A1/en not_active Abandoned
- 2007-07-03 EP EP07787001A patent/EP2049478B1/en active Active
- 2007-07-03 WO PCT/EP2007/056675 patent/WO2008003697A1/en active Application Filing
- 2007-07-03 JP JP2009517252A patent/JP5283620B2/ja not_active Expired - Fee Related
- 2007-07-03 EA EA200970085A patent/EA016076B1/ru not_active IP Right Cessation
- 2007-07-03 KR KR1020097002352A patent/KR101398264B1/ko not_active IP Right Cessation
- 2007-07-03 ES ES07787001T patent/ES2385505T3/es active Active
- 2007-07-03 BR BRPI0714062-2A patent/BRPI0714062A2/pt not_active IP Right Cessation
- 2007-07-03 SI SI200730962T patent/SI2049478T1/sl unknown
- 2007-07-03 US US11/772,977 patent/US7718693B2/en not_active Expired - Fee Related
- 2007-07-03 AU AU2007271182A patent/AU2007271182B2/en not_active Ceased
- 2007-07-03 MX MX2009000117A patent/MX2009000117A/es active IP Right Grant
- 2007-07-03 PT PT07787001T patent/PT2049478E/pt unknown
- 2007-07-04 TW TW096124227A patent/TW200819127A/zh unknown
- 2007-07-04 AR ARP070102985A patent/AR061815A1/es unknown
- 2007-07-04 PE PE2007000855A patent/PE20080997A1/es not_active Application Discontinuation
-
2008
- 2008-12-19 CR CR10545A patent/CR10545A/es unknown
- 2008-12-25 IL IL196181A patent/IL196181A0/en unknown
-
2009
- 2009-01-16 NO NO20090267A patent/NO20090267L/no not_active Application Discontinuation
- 2009-01-30 MA MA31599A patent/MA30607B1/fr unknown
- 2009-07-22 HK HK09106719.8A patent/HK1127604A1/xx not_active IP Right Cessation
-
2010
- 2010-02-18 US US12/708,077 patent/US8048907B2/en not_active Expired - Fee Related
-
2012
- 2012-06-18 HR HRP20120505TT patent/HRP20120505T1/hr unknown
- 2012-07-26 CY CY20121100671T patent/CY1113415T1/el unknown
-
2014
- 2014-11-10 CR CR20140515A patent/CR20140515A/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UA100227C2 (uk) | Заміщені n-фенілметил-5-оксопролін-2-аміди як антагоністи p2x7-рецептора та їх застосування | |
UA99882C2 (uk) | Похідні бензофуранілу, фармацевтична композиція та спосіб лікування захворювань (варіанти) | |
ATE489088T1 (de) | N- (phenylmethyl) -2- (1h-pyrazol-4-yl) acetamid- derivate als p2x7-antagonisten zur behandlung von schmerzen, entzündungen und neurodegeneration | |
ATE502017T1 (de) | Pyrazolderivate als p2x7-modulatoren | |
UA95644C2 (uk) | Піридазинонові похідні, фармацевтична композиція та спосіб лікування захворювань | |
MY161834A (en) | Substituted diazepan compounds as orexin receptor antagonists | |
UA99620C2 (en) | Pyridyl piperidine orexin receptor antagonists | |
MX2008012400A (es) | Azolopirimidinas como inhibidores de actividad de cannabinoide 1. | |
ZA200901037B (en) | Pyrimidone compounds as GSK-3 inhibitors | |
EA200970912A1 (ru) | Карбоксамидные производные имидазолидина в качестве модуляторов p2x7 | |
WO2010008831A3 (en) | Compounds and methods for modulating g protein-coupled receptors | |
WO2007095124A3 (en) | Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors | |
MX2009006540A (es) | Derivados de ester y amida de indazolilo para el tratamiento de enfermedades mediadas por un receptor de glucocorticoides. | |
UA96308C2 (uk) | Антагоністи рецептора глюкагону, композиція, що містить такі сполуки, і їх застосування | |
WO2008064018A8 (en) | Thienopyrimidinones for treatment of inflammatory disorders and cancers | |
EA200970065A1 (ru) | Производные пиперазинила, предназначенные для лечения заболеваний, опосредованных рецептором gpr38 | |
WO2008008551A3 (en) | 2-substituted proline bis-amide orexin receptor antagonists | |
MY165113A (en) | Piperidinone carboxamide azaindane cgrp receptor antagonists | |
GEP20135744B (en) | Quinuclidine carbonate derivatives and medicinal compositions containing the same | |
TW200720260A (en) | Prokineticin 1 receptor antagonists | |
TW200716566A (en) | Prokineticin 2 receptor antagonists | |
GB0611907D0 (en) | Compounds | |
MX2008002805A (es) | Derivados de carboxamida como antagonistas del receptor muscarinico. | |
TN2011000282A1 (en) | Alkaloid aminoester derivatives and medicinal composition thereof | |
GEP20135806B (en) | Lactams as beta secretase inhibitors |